Q-omics provides the consensus-scored TRAV36DV7 profile across patient tissues and cancer cell-line models. TRAV36DV7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TRAV36DV7 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, TRAV36DV7 RNA expression shows 11,761 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where TRAV36DV7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV36DV7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV36DV7 survival associations across molecular data types. TRAV36DV7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV36DV7 RNA expression–survival associations across cancer types. High TRAV36DV7 expression shows favorable associations in BLCA, HNSC, SKCM, CESC, LAML and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TRAV36DV7 RNA expression.
This table summarizes TRAV36DV7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV36DV7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV36DV7 shows lower tumor expression in LUSC and COAD and higher tumor expression in KIRC, STAD, BRCA and UCEC. The KIRC box plot shows higher TRAV36DV7 RNA expression in tumor versus normal tissue (log2 FC = +0.750, t-test p < 0.001).
This table shows molecular features associated with TRAV36DV7 in patient tissues and cancer cell lines. In patient samples, TRAV36DV7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
